About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North. Short name: SEZI.

Press releases

Senzime’s Interim report quarter 2, 2018

Read more

Resolutions at Senzime AB’s (publ) annual general meeting

Read more
See all »

News

Senzime at the Innovation Pavilion

Read more

Lena Söderström appointed Biotech Builder 2018

Read more

TetraGraph Exhibition and Poster presentation at The Euroanaesthesia 2018 Annual Meeting, Copenhagen, Denmark, June 2-4

Read more
See all »